TKNO (44) MYGN (39) ACHV (44) QDEL (30) ⌘ Pro Terminal →

Anbio Biotechnology (Class A) (NNNN) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell NNNN stock right now?

Anbio Biotechnology (Class A) (NNNN) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at 84x P/E (17% return on capital) under elevated 10-year interest-rate pressure.

Q: What is NNNN's 12-month price target and RQD AI Jury consensus?

NNNN's 12-month base price target is $3.5 (range $2.73 to $46.97), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$3.72 -3.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.69

Anbio Biotechnology (Class A) (NNNN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $535.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NNNN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Anbio Biotechnology (Class A) (NASDAQ: NNNN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.72 (-3.12% 1D, market cap $535.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NNNN ranks #479 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NNNN compare to TKNO and MYGN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NNNN carries a Roarable D (45/100 RQD), trailing P/E of 83.6x, gross margin of 87.2%, and ROIC of 17.0%. By comparison, TKNO (Alpha Teknova Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NNNN?

▼

Per NNNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001982708), Anbio Biotechnology (Class A) generated $8.6M in revenue (+5.6% YoY), $6.4M in net income, and -$6.7M in free cash flow against $30.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.69 (-0.75%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNNN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY NNNN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (31% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.4 (OVERSOLD (<32))

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$4.66-32.8% Next Q

Q2 (-2Q)

Grade C-$3.13+21.7% Next Q

Q3 (-1Q)

Grade D$3.81-2.4% Next Q

Current

Grade D$3.72-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NNNN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NNNN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.47) and Max Pain ($3.91) forces dealer call-delta covering toward $46.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NNNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

29.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $3$3.72H: $45

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NNNN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

17.0% ROIC with 87.2% gross margin and -1.26% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

12/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like NNNN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Priced at 84x earnings—high expectations leave less room for a lukewarm quarter.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNNN)

✓Walkthrough of NNNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NNNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.95%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.75H $3.75L $3.33C $3.72VOL 39.0K

RES: $7.62SUP: $2.07SMA50: $5.47SMA200: $17.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NNNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NNNN Butterfly Map → + Track NNNN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +5.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NNNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NNNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NNNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNNN)

Health Care Rank #479 of 1016 ⚔️ TKNO vs NNNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NNNN vs. TKNO, MYGN, ACHV, QDEL)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Anbio Biotechnology (Class A) (NNNN) ranks #479 by composite RQD confidence (45/100, grade D) and #436 by equity capitalization ($535.3M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NNNN ACTIVE Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	Benchmark Subject
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-nnnn →
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-nnnn →
ACHV Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-nnnn →
QDEL QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	/qdel-vs-nnnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001982708

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anbio Biotechnology (Class A) (NNNN) reported GAAP revenue of $8.6M (+5.6% vs. FY2024 revenue of $8.2M , and +28.8% cumulative change since FY2023) , GAAP net income of $6.4M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (-423.9% YoY). On the balance sheet, NNNN closed FY2025 with $30.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.6M	$6.4M	-$6.7M	-$6.7M	$30.2M	—
FY2024 (FY)	2024-12-31	$8.2M	$2.4M	$2.1M	$2.1M	$18.9M	—
FY2023 (FY)	2023-12-31	$6.7M	$2.3M	$898.4K	$898.4K	—	—

3. NNNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NNNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NNNN compare to TKNO and MYGN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NNNN?

Where is NNNN trading relative to its 50-day, 200-day, and 52-week technical levels?

NNNN last traded at $3.72 (-3.12% on volume of 41,343 shares), positioning the stock -31.99% below its 50-day simple moving average ($5.47) and -78.53% below its 200-day simple moving average ($17.33). Across its 52-week range of $3.09 to $44.73, NNNN sits at the 1.5% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.25 to $4.19).

NNNN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NNNN stock right now?

Anbio Biotechnology (Class A) (NNNN) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at 84x P/E (17% return on capital) under elevated 10-year interest-rate pressure.

What is NNNN's 12-month price target and RQD AI Jury consensus?

NNNN's 12-month base price target is $3.5 (range $2.73 to $46.97), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NNNN RQD Cockpit NNNN 12M Forecast NNNN Earnings & Move NNNN Dividends & DRIP NNNN Insiders & 13F NNNN Whale Options NNNN Profit Sankey NNNN News & Why